Expert Updates in the Management of AML and CLL

1. Increased knowledge regarding the emerging clinical trial data for newer therapies used to treat AML
2. Increased knowledge regarding the recently approved treatment options for agents used in patients with AML
3. Increased knowledge regarding the emerging clinical trial data for newer therapies used to treat CLL

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Maher A. Karam, MD
Maher
UT MD Anderson Cancer Center

Activity Director

Nothing to disclose

Courtney D. DiNardo, MD
Associate Professor
The University of Texas MD Anderson Cancer Center

Faculty

Membership on advisory committees or review panels, board membership, etc.-Agios -|Membership on advisory committees or review panels, board membership, etc.-Celgene-|Membership on advisory committees or review panels, board membership, etc.-Abbvie-|Stocks or stock options, excluding diversified mutual funds-Notable Labs-|Honoraria-Novartis AG-|Honoraria-Aprea-|Honoraria-Gilead-|Honoraria-Foghorn Therapeutics-

Amir T Fathi, MD
Associate Professor of Medicine
Massachusetts General Hospital / Harvard Medical School

Faculty

Paid consultant-Agios-|Paid consultant-Takeda Pharmaceuticals, Inc.-|Paid consultant-Pfizer, Inc.-|Paid consultant-Trillium-|Paid consultant-Abbvie-|Paid consultant-Kura-|Paid consultant-Blueprint-|Paid consultant-Astellas-|Paid consultant-Genentech, Inc.-|Paid consultant-Foghorn-|Paid consultant-Bristol-Myers Squibb-|Paid consultant-Kite-|Paid consultant-Morphosys-|Paid consultant-Ipsen-|Grant or research support-Agios-|Grant or research support-Bristol-Myers Squibb-|Grant or research support-Abbvie-|Grant or research support-Servier-

John M. Pagel, MD, MD, PhD
Chief of Hematologic Malignancies
Swedish Cancer Institute

Faculty

Paid consultant-AstraZeneca-|Paid consultant-Gilead-|Paid consultant-Incyte/Morphosys-|Paid consultant-Epizyme-|Paid consultant-Beigene-|Paid consultant-MEI Pharma-|Paid consultant-Actinium Pharmaceuticals-

Philip Thompson, MBBS
Assistant Professor
M.D. Anderson Cancer Center

Faculty

Membership on advisory committees or review panels, board membership, etc.-Adaptive Biotechnologies-|Honoraria-Janssen-|Membership on advisory committees or review panels, board membership, etc.-AbbVie-

Angelic Castillo
CE Conference Planner
University of Texas MD Anderson Cancer Center

Other Planning Committee Member

Nothing to disclose

Lisa Cockrell, PhD
Medical Education Director
Medscape

Other Planning Committee Member

Nothing to disclose

Stephanie Corder, Doctor of Nursing
Medscape

Other Planning Committee Member

Nothing to disclose

Brittney French , BS
Webmd

Other Planning Committee Member

Nothing to disclose

Haleh Kadkhoda, MS
Medscape Oncology

Other Planning Committee Member

Nothing to disclose

Amy A Sabek, MBA
Senior Manager
Medscape Education

Other Planning Committee Member

Nothing to disclose

SUPPORT ACKNOWLEDGEMENT  The conference organizing committee wishes to express appreciation to the following companies for their commitment to continuing medical education by providing an educational grant in support of this conference: AbbVie Inc.  Astellas Pharma Global Development, Inc. Janssen Scientific Affairs, LLC and Pharmacyclics LLC, an AbbVie Company